NO20011440L - mGluR5-antagonister for behandling av smerte og angst - Google Patents

mGluR5-antagonister for behandling av smerte og angst

Info

Publication number: NO20011440L
Authority: NO; Norway
Prior art keywords: pain; treatment; anxiety; antagonists; mglur5 antagonists
Prior art date: 1998-10-02

Application number

NO20011440A

Other languages

English (en)

Norwegian (no)

Other versions

NO20011440D0 (no

Inventor

Hans Allgeier

Nicholas David Cosford

Peter Josef Flor

Original Assignee

Novartis Ag

Sibia Neurosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-02

Filing date

2001-03-21

Publication date

2001-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011440(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-02 Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en

2001-03-21 Application filed by Novartis Ag, Sibia Neurosciences Inc filed Critical Novartis Ag

2001-03-21 Publication of NO20011440D0 publication Critical patent/NO20011440D0/no

2001-05-15 Publication of NO20011440L publication Critical patent/NO20011440L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)

NO20011440A 1998-10-02 2001-03-21 mGluR5-antagonister for behandling av smerte og angst NO20011440L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9821503.1A GB9821503D0 (en)	1998-10-02	1998-10-02	Organic compounds
US22081398A	1998-12-23	1998-12-23
PCT/EP1999/007239 WO2000020001A1 (fr)	1998-10-02	1999-09-30	Antagonistes du mglur pour le traitement de la douleur et de l'angoisse

Publications (2)

Publication Number	Publication Date
NO20011440D0 NO20011440D0 (no)	2001-03-21
NO20011440L true NO20011440L (no)	2001-05-15

Family

ID=26314451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20011440A NO20011440L (no)	1998-10-02	2001-03-21	mGluR5-antagonister for behandling av smerte og angst

Country Status (21)

Country	Link
EP (1)	EP1117403B1 (fr)
JP (1)	JP2002526408A (fr)
KR (1)	KR20010088832A (fr)
CN (1)	CN1187048C (fr)
AT (1)	ATE255894T1 (fr)
AU (1)	AU765644B2 (fr)
BR (1)	BR9914215A (fr)
CA (1)	CA2345137A1 (fr)
DE (1)	DE69913548T2 (fr)
DK (1)	DK1117403T3 (fr)
ES (1)	ES2213389T3 (fr)
HU (1)	HUP0200553A3 (fr)
ID (1)	ID29095A (fr)
IL (2)	IL142047A0 (fr)
NO (1)	NO20011440L (fr)
NZ (1)	NZ510743A (fr)
PL (1)	PL202906B1 (fr)
PT (1)	PT1117403E (fr)
RU (1)	RU2232017C2 (fr)
SK (1)	SK4382001A3 (fr)
WO (1)	WO2000020001A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0005700D0 (en) *	2000-03-09	2000-05-03	Glaxo Group Ltd	Therapy
KR100545906B1 (ko)	2000-12-22	2006-01-26	에프. 호프만-라 로슈 아게	ｍＧｌｕＲ 1 길항물질로서의 테트라하이드로-(벤조 또는티에노)-아제핀-피라진 및 트리아진 유도체
GB0128996D0 (en)	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
SE0303418D0 (sv) *	2003-12-17	2003-12-17	Astrazeneca Ab	New use 1
SE0303419D0 (sv) *	2003-12-17	2003-12-17	Astrazeneca Ab	New use 11
FR2883180B1 (fr) *	2005-03-18	2007-05-25	Pierre Fabre Medicament Sa	Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
DE102005062985A1 (de) *	2005-12-28	2007-07-05	Grünenthal GmbH	Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
RS55585B1 (sr)	2006-11-22	2017-06-30	Clinical Research Associates LLC	Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) *	2009-12-17	2013-11-19	Hoffmann-La Roche Inc	Ethynyl compounds useful for treatment of CNS disorders
WO2011092293A2 (fr)	2010-02-01	2011-08-04	Novartis Ag	Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
AR080055A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011095450A1 (fr)	2010-02-02	2011-08-11	Novartis Ag	Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
EP2544688B1 (fr)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Procédés et compositions pour le traitement du syndrome d'angelman
WO2011150380A1 (fr)	2010-05-28	2011-12-01	Xenoport, Inc.	Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (fr)	2010-10-21	2012-04-26	Massachusetts Institute Of Technology	Méthodes de traitement de troubles épileptiques
US8546416B2 (en)	2011-05-27	2013-10-01	Novartis Ag	3-spirocyclic piperidine derivatives as ghrelin receptor agonists
EP2557183A1 (fr)	2011-08-12	2013-02-13	Siemens Aktiengesellschaft	Procédé de fonctionnement d'une bougie continue pour le traitement d'un produit de laminage
CA2867043A1 (fr)	2012-05-03	2013-11-07	Novartis Ag	Sel de l-malate de derives de 2,7-diaza-spiro[4.5]dec-7-yle et ses formes cristallines a titre d'agonistes des recepteurs de ghreline
CN107849006B (zh)	2015-06-03	2020-11-13	豪夫迈·罗氏有限公司	乙炔基衍生物
KR20200035035A (ko)	2017-07-31	2020-04-01	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3459939A1 (fr)	2017-09-26	2019-03-27	Pragma Therapeutics	Nouveaux composés hétérocycliques comme modulateurs de mglur7
KR102027368B1 (ko) *	2018-05-29	2019-10-01	서울대학교산학협력단	통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2056983T3 (es) *	1988-03-21	1994-10-16	Boehringer Ingelheim Pharma	Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives

1999
- 1999-09-30 WO PCT/EP1999/007239 patent/WO2000020001A1/fr not_active Ceased
- 1999-09-30 KR KR1020017004152A patent/KR20010088832A/ko not_active Ceased
- 1999-09-30 EP EP99948905A patent/EP1117403B1/fr not_active Revoked
- 1999-09-30 DK DK99948905T patent/DK1117403T3/da active
- 1999-09-30 NZ NZ510743A patent/NZ510743A/en unknown
- 1999-09-30 DE DE69913548T patent/DE69913548T2/de not_active Revoked
- 1999-09-30 ID IDW20010730A patent/ID29095A/id unknown
- 1999-09-30 CN CNB998117110A patent/CN1187048C/zh not_active Expired - Fee Related
- 1999-09-30 SK SK438-2001A patent/SK4382001A3/sk unknown
- 1999-09-30 HU HU0200553A patent/HUP0200553A3/hu unknown
- 1999-09-30 JP JP2000573360A patent/JP2002526408A/ja active Pending
- 1999-09-30 AT AT99948905T patent/ATE255894T1/de active
- 1999-09-30 AU AU61984/99A patent/AU765644B2/en not_active Ceased
- 1999-09-30 IL IL14204799A patent/IL142047A0/xx active IP Right Grant
- 1999-09-30 RU RU2001111868/14A patent/RU2232017C2/ru not_active IP Right Cessation
- 1999-09-30 ES ES99948905T patent/ES2213389T3/es not_active Expired - Lifetime
- 1999-09-30 CA CA002345137A patent/CA2345137A1/fr not_active Abandoned
- 1999-09-30 PL PL346876A patent/PL202906B1/pl not_active IP Right Cessation
- 1999-09-30 PT PT99948905T patent/PT1117403E/pt unknown
- 1999-09-30 BR BR9914215-5A patent/BR9914215A/pt not_active Application Discontinuation
2001
- 2001-03-15 IL IL142047A patent/IL142047A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011440A patent/NO20011440L/no unknown

Also Published As

Publication number	Publication date
JP2002526408A (ja)	2002-08-20
AU6198499A (en)	2000-04-26
PL346876A1 (en)	2002-03-11
AU765644B2 (en)	2003-09-25
IL142047A (en)	2007-09-20
PL202906B1 (pl)	2009-08-31
WO2000020001A1 (fr)	2000-04-13
NZ510743A (en)	2003-10-31
SK4382001A3 (en)	2001-08-06
BR9914215A (pt)	2001-07-03
EP1117403B1 (fr)	2003-12-10
ID29095A (id)	2001-07-26
CN1321087A (zh)	2001-11-07
IL142047A0 (en)	2002-03-10
ES2213389T3 (es)	2004-08-16
ATE255894T1 (de)	2003-12-15
HUP0200553A3 (en)	2002-11-28
DE69913548D1 (de)	2004-01-22
DK1117403T3 (da)	2004-04-13
HUP0200553A2 (hu)	2002-07-29
PT1117403E (pt)	2004-04-30
DE69913548T2 (de)	2004-09-23
EP1117403A1 (fr)	2001-07-25
KR20010088832A (ko)	2001-09-28
NO20011440D0 (no)	2001-03-21
RU2232017C2 (ru)	2004-07-10
CA2345137A1 (fr)	2000-04-13
CN1187048C (zh)	2005-02-02

Publication	Publication Date	Title
NO20011440D0 (no)	2001-03-21	mGluR5-antagonister for behandling av smerte og angst
NO20020770D0 (no)	2002-02-15	Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av fedme
DE60026704D1 (de)	2006-05-11	(S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60233040D1 (de)	2009-09-03	Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
BR0107565A (pt)	2003-02-11	Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
IS6560A (is)	2002-09-20	Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
ATE284388T1 (de)	2004-12-15	Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
CY1108610T1 (el)	2014-04-09	Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
NO20024775D0 (no)	2002-10-03	Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DE60108857D1 (de)	2005-03-17	Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE266420T1 (de)	2004-05-15	Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
DE50114605D1 (de)	2009-02-05	No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60016047D1 (de)	2004-12-23	Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
NO20024776D0 (no)	2002-10-03	Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20024777L (no)	2002-12-03	Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
TR200402230T4 (tr)	2004-10-21	O-ikameli 6-metil-tramadol-türevleri
ITRM990426A0 (it)	1999-07-05	Impiego di inibitori della sostanza p per il trattamento degli adenocarcinomi.
ATE358483T1 (de)	2007-04-15	Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
BR0314139A (pt)	2005-07-12	Derivados de 1,4-pirazina substituìdos
NO20032156L (no)	2003-05-13	Behandling av angstforstyrrelser
NO20005548L (no)	2000-12-04	Mykobakterieinhibitorer
BR0206918A (pt)	2004-02-03	Uso de iloperidona
TR200003084T2 (tr)	2001-02-21	Paroxetine askorbat
ITTO20000068V0 (it)	2000-05-04	Plantaroller massaggiatore, distensore e stimolatore dell'arco plantare.